For patients with chronic lymphocytic leukemia who cannot tolerate Bruton tyrosine kinase inhibitors, zanubrutinib shows promise, improving outcomes.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/zanubrutinib-benefits-btk-intolerant-leukemia-2025a1000q6c?src=rss
Author :
Publish date : 2025-09-30 12:32:00
Copyright for syndicated content belongs to the linked Source.